Compare AMCI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCI | CRBP |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 134.8M |
| IPO Year | N/A | 2014 |
| Metric | AMCI | CRBP |
|---|---|---|
| Price | $7.14 | $9.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $46.17 |
| AVG Volume (30 Days) | 50.6K | ★ 152.1K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $33.37 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $3.60 | $4.64 |
| 52 Week High | $15.75 | $20.56 |
| Indicator | AMCI | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 70.35 |
| Support Level | $5.84 | $9.86 |
| Resistance Level | $7.75 | $11.64 |
| Average True Range (ATR) | 0.66 | 0.58 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 74.62 | 96.56 |
AMC Robotics Corp is an artificial intelligence services company that develops robotic solutions designed to support operational efficiency across sectors such as logistics and manufacturing. The company develops robotics and automation technologies designed to improve logistics operations. Its robots use sensors and visual AI to support real-time decision-making, contributing to safer and more efficient warehouse operations. It builds autonomous robots for use in logistics and warehousing.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.